Arthur Fratamico, Radiant Biotherapeutics CEO
September 11, 2024 07:00 AM EDT
Financing
Startups

Ra­di­ant Bio snags $35M for an­ti­body plat­form, with GSK and Re­gen­eron part­ner­ships

Kyle LaHucik

Senior Reporter

A drug de­vel­op­er aim­ing to cre­ate more po­tent, ef­fec­tive an­ti­bod­ies un­veiled a $35 mil­lion Se­ries A on Wednes­day with the sup­port of the Bill …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Bad trip: How cul­ture con­flict and a need for cash near­ly broke Lykos

Cigna sues FTC, call­ing for with­draw­al of 'bi­ased, er­ro­neous' PBM re­port

No­var­tis’ Kisqali snags FDA ap­proval to re­duce re­cur­rence in pa­tients with ear­ly forms of breast can­cer

23andMe heads to ES­MO to tout its two clin­i­cal-stage drugs af­ter scrap­ping dis­cov­ery team

CD­MO Serán sets out to build first com­mer­cial fa­cil­i­ty, with a $200M in­vest­ment led by Bain Cap­i­tal

sponsored

Break­ing down si­los with a new quan­ti­ta­tive ap­proach to drug de­vel­op­ment

A service from the Financial Times